RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Glycemic Improvement with Canagliflozin is Durable in T2DM Patients on Metformin
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 17
SP 24
OP 25
DO 10.1177/155989771317016
UL http://mdc.sagepub.com/content/13/17/24.abstract
AB The sodium glucose cotransporter 2 inhibitor canagliflozin is associated with durable glycemic improvement over 104 weeks compared with glimepiride in patients with type 2 diabetes mellitus (T2DM) on background metformin therapy. Such was the primary finding of a Phase 3 randomized, double-blind efficacy and safety study.